190 related articles for article (PubMed ID: 35484312)
21. Structural Gray Matter Alterations in Chronic Migraine: Implications for a Progressive Disease?
Neeb L; Bastian K; Villringer K; Israel H; Reuter U; Fiebach JB
Headache; 2017 Mar; 57(3):400-416. PubMed ID: 28028808
[TBL] [Abstract][Full Text] [Related]
22. Decoding pain through facial expressions: a study of patients with migraine.
Chen WT; Hsiao FJ; Coppola G; Wang SJ
J Headache Pain; 2024 Mar; 25(1):33. PubMed ID: 38462615
[TBL] [Abstract][Full Text] [Related]
23. Pathophysiology of chronic migraine and mode of action of preventive medications.
Mathew NT
Headache; 2011; 51 Suppl 2():84-92. PubMed ID: 21770930
[TBL] [Abstract][Full Text] [Related]
24. Glutamate and Its Receptors as Therapeutic Targets for Migraine.
Hoffmann J; Charles A
Neurotherapeutics; 2018 Apr; 15(2):361-370. PubMed ID: 29508147
[TBL] [Abstract][Full Text] [Related]
25. Similarities and differences between chronic migraine and episodic migraine.
Ferrari A; Leone S; Vergoni AV; Bertolini A; Sances G; Coccia CP; Ottani A; Pinetti D; Sternieri E
Headache; 2007 Jan; 47(1):65-72. PubMed ID: 17355496
[TBL] [Abstract][Full Text] [Related]
26. Increased connectivity of pain matrix in chronic migraine: a resting-state functional MRI study.
Lee MJ; Park BY; Cho S; Kim ST; Park H; Chung CS
J Headache Pain; 2019 Mar; 20(1):29. PubMed ID: 30909865
[TBL] [Abstract][Full Text] [Related]
27. Persistent ictal-like visual cortical excitability in chronic migraine.
Chen WT; Wang SJ; Fuh JL; Lin CP; Ko YC; Lin YY
Pain; 2011 Feb; 152(2):254-258. PubMed ID: 21145169
[TBL] [Abstract][Full Text] [Related]
28. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
[TBL] [Abstract][Full Text] [Related]
29. Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine?
Greco R; De Icco R; Demartini C; Zanaboni AM; Tumelero E; Sances G; Allena M; Tassorelli C
J Headache Pain; 2020 Oct; 21(1):122. PubMed ID: 33066724
[TBL] [Abstract][Full Text] [Related]
30. Serological Biomarkers of Chronic Migraine.
Cho S; Chu MK
Curr Pain Headache Rep; 2023 Oct; 27(10):531-542. PubMed ID: 37561314
[TBL] [Abstract][Full Text] [Related]
31. Improving the classification of migraine subtypes: an empirical approach based on factor mixture models in the American Migraine Prevalence and Prevention (AMPP) Study.
Lipton RB; Serrano D; Pavlovic JM; Manack AN; Reed ML; Turkel CC; Buse DC
Headache; 2014 May; 54(5):830-49. PubMed ID: 24527745
[TBL] [Abstract][Full Text] [Related]
32. Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study.
Lipton RB; Cohen JM; Bibeau K; Galic M; Seminerio MJ; Ramirez Campos V; Halker Singh RB; Ailani J
Headache; 2020 Nov; 60(10):2444-2453. PubMed ID: 33179323
[TBL] [Abstract][Full Text] [Related]
33. Differences in central facilitation between episodic and chronic migraineurs in nociceptive-specific trigeminal pathways.
Sohn JH; Kim CH; Choi HC
J Headache Pain; 2016; 17():35. PubMed ID: 27084694
[TBL] [Abstract][Full Text] [Related]
34. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers.
Buse DC; Manack A; Serrano D; Turkel C; Lipton RB
J Neurol Neurosurg Psychiatry; 2010 Apr; 81(4):428-32. PubMed ID: 20164501
[TBL] [Abstract][Full Text] [Related]
35. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II).
Blumenfeld AM; Bloudek LM; Becker WJ; Buse DC; Varon SF; Maglinte GA; Wilcox TK; Kawata AK; Lipton RB
Headache; 2013 Apr; 53(4):644-55. PubMed ID: 23458496
[TBL] [Abstract][Full Text] [Related]
36. Acute treatment optimization in episodic and chronic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.
Serrano D; Buse DC; Manack Adams A; Reed ML; Lipton RB
Headache; 2015 Apr; 55(4):502-18. PubMed ID: 25881676
[TBL] [Abstract][Full Text] [Related]
37. Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine.
Vieira DS; Naffah-Mazzacoratti Mda G; Zukerman E; Senne Soares CA; Cavalheiro EA; Peres MF
Headache; 2007 Jun; 47(6):842-7. PubMed ID: 17578532
[TBL] [Abstract][Full Text] [Related]
38. Impact of chronic migraine attacks and their severity on the endogenous μ-opioid neurotransmission in the limbic system.
Jassar H; Nascimento TD; Kaciroti N; DosSantos MF; Danciu T; Koeppe RA; Smith YR; Bigal ME; Porreca F; Casey KL; Zubieta JK; DaSilva AF
Neuroimage Clin; 2019; 23():101905. PubMed ID: 31279240
[TBL] [Abstract][Full Text] [Related]
39. Signs of temporomandibular disorders in migraine patients: a prospective, controlled study.
Stuginski-Barbosa J; Macedo HR; Bigal ME; Speciali JG
Clin J Pain; 2010 Jun; 26(5):418-21. PubMed ID: 20473049
[TBL] [Abstract][Full Text] [Related]
40. Role of glutamate and its receptors in migraine with reference to amitriptyline and transcranial magnetic stimulation therapy.
Tripathi GM; Kalita J; Misra UK
Brain Res; 2018 Oct; 1696():31-37. PubMed ID: 29859974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
